Abstract FOXM1 (Forkhead box M1) is a typical proliferation-associated transcription factor
and is also intimately involved in tumorigenesis. FOXM1 stimulates cell proliferation and cell …

Current development of targeted therapy in oncology is particularly active and concerns
principally two types of agents which are monoclonal antibodies (Mabs) and tyrosine kinase …

Tumor hypoxia is a common feature of the tumor microenvironment and has been regarded
as one of the key factors in driving the emergence of drug resistance in solid tumors. To …

Purpose: To examine the enzyme kinetics of gefitinib and erlotinib metabolism by individual
cytochrome P450 (CYP) enzymes, and to compare their effects on CYP3A activity, with the …

Chemoresistance contributes to cancer relapse and increased mortality in a variety of
cancer types, raising a pressing need to better understand the underlying mechanism …

This study was prospectively designed to evaluate a phase II study of gefitinib for non-small-
cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations …

Importance of the field: A concerted effort by the pharmaceutical industry over the last
decade has led to the successful clinical development of protein kinase inhibitors as …

Lung cancer is the leading cause of cancer-related death in both men and women.
Environmental carcinogens, particularly tobacco smoke, play a dominant role in the …

Gefitinib belongs to the small-molecule class of epidermal growth factor receptor (EGFR)
tyrosine-kinase inhibitors. It was given conditional approval by the US Food and Drug …

We aimed to investigate and compare the effects of erlotinib and gefitinib on UDP-
glucuronosyltransferase (UGT) activities and to quantitatively evaluate their drug-drug …